Clinical Trial Update: An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A [Phase 2, Phase 3]

View source ↗

Summary

An open-label Phase 2/3 trial in severe Hemophilia A evaluated the safety, efficacy, and pharmacokinetics of a recombinant factor VIII compared to recombinant h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia A | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-08-09